Century Therapeutics (IPSC) News Today $1.04 -0.13 (-10.68%) (As of 05:44 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Philadelphia cell therapy developer loses Big Pharma partnership valued at over $3BDecember 17 at 10:21 AM | bizjournals.comFmr LLC Cuts Stake in Century Therapeutics, Inc. (NASDAQ:IPSC)Fmr LLC lowered its position in Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 14.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,521,511 shares of the company's stock after selling 428,768 shares during the quarter. Fmr LLC ownedDecember 14, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Stock Price Down 4.3% - What's Next?December 12, 2024 | americanbankingnews.comCentury Therapeutics (NASDAQ:IPSC) Trading Down 4.3% - Here's What HappenedCentury Therapeutics (NASDAQ:IPSC) Shares Down 4.3% - Here's What HappenedDecember 12, 2024 | marketbeat.comCentury Therapeutics to Present at Piper Sandler 36th Annual Healthcare ConferenceNovember 29, 2024 | msn.comLeerink Partners Reaffirms Their Buy Rating on Century Therapeutics (IPSC)November 28, 2024 | markets.businessinsider.comCentury Therapeutics to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 26, 2024 | globenewswire.comWhat is HC Wainwright's Forecast for IPSC FY2024 Earnings?Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Equities researchers at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Century Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst M. Kapoor now anticNovember 8, 2024 | marketbeat.comWhat is William Blair's Forecast for IPSC FY2024 Earnings?Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Research analysts at William Blair upped their FY2024 earnings per share (EPS) estimates for shares of Century Therapeutics in a report released on Tuesday, November 5th. William Blair analyst S. Corwin now expects that the company will posNovember 8, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Given New $11.00 Price Target at Chardan CapitalChardan Capital lowered their price target on Century Therapeutics from $17.00 to $11.00 and set a "buy" rating for the company in a research report on Thursday.November 7, 2024 | marketbeat.comCentury Therapeutics Reports Q3 Results & Strategic UpdatesNovember 6, 2024 | markets.businessinsider.comJoin Century Therapeutics at Guggenheim’s Healthcare Innovation Conference!November 6, 2024 | msn.comHC Wainwright Cuts Century Therapeutics (NASDAQ:IPSC) Price Target to $5.00HC Wainwright reduced their target price on Century Therapeutics from $9.00 to $5.00 and set a "buy" rating for the company in a report on Wednesday.November 6, 2024 | marketbeat.comCentury Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual MeetingNovember 5, 2024 | markets.businessinsider.comCentury Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 5, 2024 | globenewswire.comCentury Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation ConferenceNovember 4, 2024 | markets.businessinsider.comCentury Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation ConferenceNovember 4, 2024 | globenewswire.comWe're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn RateOctober 28, 2024 | finance.yahoo.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Growth in Short InterestCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the target of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 3,490,000 shares, a growth of 6.4% from the September 15th total of 3,280,000 shares. Based on an average daily trading volume, of 331,100 shares, the short-interest ratio is presently 10.5 days. Approximately 10.8% of the shares of the company are sold short.October 16, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comWatch out, CFOs: cybercrime is booming, says former White House advisorSeptember 30, 2024 | fortune.comCentury Therapeutics Announces Strategic Leadership AppointmentsSeptember 27, 2024 | msn.comCentury Therapeutics Names Morgan Conn Chief Financial OfficerSeptember 26, 2024 | marketwatch.comCentury Therapeutics Appoints Morgan Conn As CFOSeptember 26, 2024 | markets.businessinsider.comCentury Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific OfficerSeptember 26, 2024 | globenewswire.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Stake Cut by Federated Hermes Inc.Federated Hermes Inc. decreased its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 55.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 276,163 shares of the company's stocSeptember 23, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Shares Up 5.5%Century Therapeutics (NASDAQ:IPSC) Shares Up 5.5%September 10, 2024 | marketbeat.comCentury Therapeutics, Inc. Expected to Post Q3 2024 Earnings of ($0.41) Per Share (NASDAQ:IPSC)Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) - Research analysts at HC Wainwright increased their Q3 2024 earnings per share estimates for shares of Century Therapeutics in a note issued to investors on Thursday, August 15th. HC Wainwright analyst M. Kapoor now expects that the companyAugust 19, 2024 | marketbeat.comHC Wainwright Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $9.00HC Wainwright lowered their target price on Century Therapeutics from $11.00 to $9.00 and set a "buy" rating for the company in a report on Thursday.August 15, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Issues Quarterly Earnings ResultsCentury Therapeutics (NASDAQ:IPSC - Get Free Report) announced its earnings results on Thursday. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.12. The business had revenue of $0.77 million for the quarter, compared to the consensus estimate of $0.55 million. Century Therapeutics had a negative return on equity of 59.74% and a negative net margin of 9,742.41%.August 11, 2024 | marketbeat.comBuy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of CompetitorsAugust 10, 2024 | markets.businessinsider.comHold Rating on Century Therapeutics Amid Early-Stage Trials and Competitive LandscapeAugust 9, 2024 | markets.businessinsider.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Moderate Buy" by AnalystsShares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommeAugust 8, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Research Coverage Started at Rodman & RenshawRodman & Renshaw began coverage on shares of Century Therapeutics in a research note on Thursday. They issued a "buy" rating and a $6.00 price objective for the company.August 8, 2024 | marketbeat.comCentury Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 8, 2024 | globenewswire.comShort Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Grows By 14.7%Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,790,000 shares, a growth of 14.7% from the June 15th total of 1,560,000 shares. Based on an average daily volume of 202,000 shares, the days-to-cover ratio is currently 8.9 days. Approximately 5.2% of the company's shares are sold short.July 17, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Trading Down 7.7%Century Therapeutics (NASDAQ:IPSC) Trading Down 7.7%July 16, 2024 | marketbeat.comGregory Russotti Sells 5,000 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC) StockJune 25, 2024 | insidertrades.comInsider Selling: Century Therapeutics, Inc. (NASDAQ:IPSC) Insider Sells 5,000 Shares of StockCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) insider Gregory Russotti sold 5,000 shares of the company's stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $2.84, for a total value of $14,200.00. Following the sale, the insider now directly owns 277,319 shares of the company's stock, valued at $787,585.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.June 24, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Price Target Raised to $12.00Piper Sandler lifted their target price on shares of Century Therapeutics from $9.00 to $12.00 and gave the stock an "overweight" rating in a research report on Monday.June 17, 2024 | marketbeat.comAvidity Partners Management LP Increases Stock Holdings in Century Therapeutics, Inc. (NASDAQ:IPSC)Avidity Partners Management LP increased its holdings in shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Free Report) by 23.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,355,000 shares of thJune 11, 2024 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $11.00 target price on shares of Century Therapeutics in a research note on Tuesday.June 4, 2024 | marketbeat.comCentury Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual MeetingJune 3, 2024 | globenewswire.comBuy Rating Affirmed for Century Therapeutics on Promising CNTY-101 Prospects and Strong Financial FootingMay 16, 2024 | markets.businessinsider.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Sees Large Decline in Short InterestCentury Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) was the recipient of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 1,560,000 shares, a drop of 9.8% from the April 15th total of 1,730,000 shares. Approximately 5.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 194,700 shares, the short-interest ratio is currently 8.0 days.May 15, 2024 | marketbeat.comBuy Rating Affirmed for Century Therapeutics Amid Promising Trials and Strategic AcquisitionsMay 11, 2024 | markets.businessinsider.comCentury Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...May 10, 2024 | finance.yahoo.comCentury Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual MeetingMay 10, 2024 | finance.yahoo.comHC Wainwright Lowers Century Therapeutics (NASDAQ:IPSC) Price Target to $11.00HC Wainwright dropped their target price on shares of Century Therapeutics from $13.00 to $11.00 and set a "buy" rating on the stock in a report on Friday.May 10, 2024 | marketbeat.comIPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024May 9, 2024 | investorplace.com Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin IPSC Media Mentions By Week IPSC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSC News Sentiment▼0.160.54▲Average Medical News Sentiment IPSC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSC Articles This Week▼41▲IPSC Articles Average Week Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News PROC News NGNE News BTMD News VYGR News DSGN News CTNM News KMDA News SLRN News CGC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPSC) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
